A Anvisa (Agencia Nacional de Vigilância Sanitária) anunciou, na manhã dessa quinta-feira (29), a aprovação de cinco novos medicamentos com GLP-1. As canetas emagrecedoras à base de liraglutida e semaglutida estão ligadas ao tratamento de diabetes e obesidade ao controlar a glicose no sangue e o apetite.

As canetas emagrecedoras chegaram ao Brasil e fevereiro de 2016, após a Anvisa aprovar o uso de medicamentos com liraglutida (inicialmente com o medicamento Saxenda para o controle crônico do peso). Desde então, a Anvisa já aprovou 20 canetas em 2026.

Confira abaixo as canetas aprovadas e suas indicações:

• Aribet (liraglutida): indicado para tratamento de diabetes. Registro concedido à empresa Farma Vision Importação e Exportação de Medicamentos Ltda, com fabricação da empresa indiana Biocon
• Lyrza (liraglutida): indicado para tratamento de obesidade, em conjunto com exercícios físicos e mudança na alimentação. Registro concedido à empresa Farma Vision Importação e Exportação de Medicamentos Ltda, com fabricação da empresa indiana Biocon

• Wylovol (liraglutida): indicado para tratamento de obesidade, em conjunto com exercícios físicos e mudança na alimentação. Registro concedido à empresa Farma Vision Importação e Exportação de Medicamentos Ltda, com fabricação da empresa indiana Biocon

• Embeltah (semaglutida): indicado para tratamento de diabetes. Registro concedido à empresa Dr.Reddys Farmacêutica do Brasil Ltda, com fabricação da empresa indiana OneSource Specialty

• Sevema (semaglutida): indicado para tratamento de diabetes- registro da empresa Aché Laboratórios Farmacêuticos S.A, com fabricação da empresa indiana OneSource Specialty

Anvisa aprova mais cinco canetas emagrecedoras | CNN NOVO DIA

Entenda mais sobre os medicamentos

A semaglutida é um medicamento que funciona como se fosse uma “cópia” melhorada de um hormônio que o nosso próprio corpo produz no intestino, chamado GLP-1. Ele atua no cérebro, fornecendo sensação de saciedade; no estômago, reduzindo a velocidade da digestão e impedindo que o estômago esvazie muito rápido; e no pâncreas, ajudando a regular os níveis de açúcar no sangue, com aplicações semanais.

A liraglutida é outro medicamento da mesma família da semaglutida (os chamados análogos do GLP-1), mas pertence a uma geração anterior. Ele também atua no cérebro, estômago e intestino, mas com aplicações diárias.

Canetas emagrecedoras: estudo lista novos possíveis efeitos colaterais

*Sob supervisão de Carolina Figueiredo

• Telehealth company Ro is launching an AI agent trained on customer data.
• The agent can recommend prescription changes, schedule deliveries, or write memos to a doctor.
• Eventually, Ro hopes to make it a "quarterback" for care. Will it improve outcomes?

Wouldn't it be great if we all had a little, digital minion handling all the small back-and forth chores of our medical care?

On Thursday, Ro is officially announcing the launch of its new AI health agent, designed to do more than a health inquiry on ChatGPT. It's the latest in a long lineup of healthcare agents — from insurers, telehealth providers, electronic health record systems, and regular chatbots — promising to cut down patient wait times, increase access to care, and improve personalized health recommendations with AI.

Ro CEO and co-founder Zach Reitano gave Business Insider an exclusive preview of Ro's new agent, called Robin, showing us how the tool could be used to perform routine tasks like managing side effects, meal planning, or making medication changes.

A founder's mission: disrupt healthcare delivery with AI agents

Reitano said this isn't just about making life more convenient for Ro's current subscribers, though that is the starting point. His long-term goal is to identify pain points where Ro customers need to seek out specialists for common conditions or prescriptions, then start offering more and more of that care in-house, becoming your go-to "quarterback" for the entire American healthcare system.

"I think it's very unlikely to me that one provider or one system handles 100% of someone's care, but I do think it is quite likely that there is one place in someone's life that serves as that quarterback and helps them navigate the rest of the healthcare system," he said. "We hope to be able to just continue to increase those concentric circles, where instead of saying you might be better suited outside of the Ro ecosystem, we would want you to be better suited in it."

When I asked him if his "ultimate goal" is to become a full-service virtual clinic, he said yeah, that's the hope.

For now, Ro's AI agent uses information that's already stored in the app, including notes from doctors, patient feedback, prescriptions, and Apple Health data to try to personalize recommendations for medication changes, dosing tweaks, or habits that might improve side effects.

It's meant to be more instinctively knowledgeable about your health than ChatGPT — requiring less prompting or uploading health data, since it already has information about patients on file. It can suggest a change in medication, and then go ahead and write a first draft of a note to your doctor, if you want it to.

"The underlying premise is: If I have your underlying health information, I can provide more informed and better things, better recommendations," telehealth researcher Dr. Ateev Mehrotra, chair of the health policy department at Brown University, said.

Only issue is, we don't yet know if that's true.

"People are giving up a lot of data for this, and so you really have to say that it truly is going to give you something," Mehrota added. "It sounds cool in theory, I'm not saying it's a bad idea. I would love some evidence before millions of Americans start doing this."

Personally, Mehrotra says he'd be much more likely to try out one of the AI agents embedded into an official electronic health record system, which has access to everything he's told his regular doctors and specialists within a specific hospital system and which — critically — has to abide by strict privacy rules. (Business Insider did not see Ro's privacy policy for Robin.)

"My health system doesn't have the weird financial incentives that we're worried about with Ro," he said. "More data, less financial incentives, I might use that."

Reitano says ultimately, it's not in his company's interests to go after short-term profits at the expense of a good patient experience.

"We fight for patients, and we serve you, and if we don't, then we go out of business," he said.

• Eli Lilly is developing a more potent weight-loss drug called retatrutide.
• In the first head-to-head trial versus Ozempic, retatrutide takers lost roughly twice as much weight.
• Retatrutide is not FDA-approved yet, but some peptide sellers are skirting the law.

Gym bros call it "reta." Eli Lilly is calling it the winner.

On Wednesday, the pharmaceutical giant announced the results of the first clinical trial pitting Ozempic against its newest, most powerful, and yet-to-be-approved next-generation injectable medication for obesity and diabetes: retatrutide.

Retatrutide won — and it wasn't even close. Type 2 diabetes patients on the highest dose of Ozempic (2 mg) lost an average of 21 pounds over a period of about a year and a half on the drug. Those on retatrutide lost an average of 44 pounds (9 mg) to 47 pounds (12 mg) during that same time. Patients also saw steeper reductions in their A1C, a key marker of blood sugar control (2.2% vs 1.8%).

"We believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions," Eli Lilly's Kenneth Custer, the president of Lilly Cardiometabolic, said in a release.

They're calling it 'King Kong'

Ozempic (from Novo Nordisk) was the very first medication of its kind — a novel peptide that mimics one gut hormone, called GLP-1.

Several years later, Mounjaro (from Eli Lilly) was approved, mimicking two hormones, GLP-1 and GIP, and delivering stronger results.

Insiders are calling Eli Lilly's retatrutide the "triple G" or "King Kong" for weight loss because it mimics three hormones: GLP-1, GIP, and a third peptide hormone called glucagon, which helps break down stored fat into energy. Some say it could rival bariatric surgery in clinical results in terms of weight loss.

Eli Lilly is expected to submit retatrutide to the US Food and Drug Administration for approval in early 2027. If all goes well, it could be available sometime next year, for conditions including obesity, obesity-related sleep apnea, and knee osteoarthritis.

In this clinical trial, side effect profiles were generally similar between patients taking Ozempic and retatrutide, but slightly more patients on retatrutide reported diarrhea, while constipation was slightly more common among Ozempic-takers. People on retatrutide also had slightly higher rates of a rare side effect called dysesthesia, triggering tingling, skin-on-fire type sensations.

The clinical trial results have not yet been peer-reviewed or published in a medical journal, but were released as the company prepares to announce its quarterly earnings on Thursday.

Knock-off reta is already booming on the black market

The drug, which is still in clinical trials, has attracted copycat peptide sellers shipping powders labeled "reta" from overseas, stoking a gray market of do-it-yourself injections. Bodybuilders say it helps shred fat and reduce appetite, with fewer side effects than other injectable weight-loss pens.

But nobody really knows exactly what they are taking, though their results seem to roughly mirror what happens when people take the real thing in clinical trials.

In an unusual move, Eli Lilly addressed the pre-approval black-market hype in their release announcing the latest results.

"Retatrutide is an investigational molecule that has not been approved by FDA or any regulatory organization anywhere in the world," the company said in a statement. "Anyone purporting to sell retatrutide to consumers is breaking the law."